Organ-Tumor-on-a-Chip Market by Type: Global Opportunity Analysis and Industry Forecast, 2021-2030

The global organ-tumor-on-a-chip market was valued at $5,937.27 thousand in 2020, and is projected to reach $117,471.41 thousand by 2030, registering a CAGR of 34.3% from 2021 to 2030.



Organ-tumor-on-a-chip is a miniature cell culture device that simulates tumor cell tissue structure and functional units in vitro. Tumor chips can ideally reproduce specific key aspects of the tumor microenvironment, such as biochemical gradients and niche factors, dynamic cell-cell and cell-matrix interactions, and complex tissue structure comprised of tumor and stromal cells. The capability of microfluidic devices to integrate all the necessary components in a less than 1-inch silicon chip along with the advances in micro electromechanical systems (MEMS) led to highly efficient lab-on-a-chip devices (LOC).

Tumor-on-a-chip is a miniature cell culture device that simulates tumor cell tissue structure and functional units in vitro. Tumor-on-a-chip can be used to simulate tumor growth and expansion, angiogenesis, and progression from early to advanced lesions involving epithelial-mesenchymal transition (EMT), tumor cell invasion and metastasis. organ-on-a-chip systems are based on the use of microfluidics to construct tissue models Other unique features of a microfluidic platform such as its perfect length scale fitting at cellular and tissue levels as well as very small quantity of required agents made them an excellent choice for biological applications. The emerging tumor-on-a-chip platforms integrating 3D cell culture, microfluidic technology, and tissue engineering have successfully mimicked the pivotal structural and functional characteristics of the in vivo tumor microenvironment.

Factors that drive the organ-tumor-on-a-chip market include a rise in the prevalence of cancer and the rising demand of personalized medicine globally. Personalized medicine has a strong impact on the healthcare industry leading to the increase of personalized medicine worldwide, especially in cancer treatments. Furthermore, cheaper availability of organ-tumor-on-a-chip can boost market growth. While, the complex nature and less user friendly to handle can hamper growth of organ-tumor-on-a- chip market over the forecast period.

Therefore, new biomarkers and simple and efficient test methods such as a smaller sample and miniaturization, protein microarray technology does have great potential in cancer diagnosis. However, complexity of the protein microarray (chip) during the production and quantification is expected to impede the growth of protein chip market over the forecast period.

The market is expected to witness moderate growth during the forecast period, owing to technological advancement in organ-tumor-on-a-chips.

The organ-tumor-on-a-chip market is segmented on the basis of type and region.

By type, it is categorized into lung tumor-on-a-chip, bone marrow tumor-on-a-chip, brain tumor-on-a-chip, breast tumor-on-a-chip, urinary system tumor-on-a-chip, intestine tumor-on-a-chip, and liver tumor-on-a-chip. Region wise, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.

The prominent players in the market have adopted various strategies for increasing their market share. These include expansion of their geographical presence through acquisitions and developing long acting and effective products with lower adverse effects. Major players operating in the organ-tumor-on-a-chip market include Axosim Technologies LLC, Beonchip S. L., BioIVT LLC, Emulate Inc., InSphero AG, Mimetas B.V., Nortis, Inc., and Organovo Holdings, Inc.

North America accounted for the highest revenue share in the organ-tumor-on-a-chip market in 2020 and is expected to dominate over the forecast period. , Asia-Pacific is expected to grow at a highest CAGR during the forecast period.

KEY BENEFITS FOR STAKEHOLDERS

• The study provides an in-depth analysis of the global organ-tumor-on-a-chip market along with the current trends and future estimations to elucidate the imminent investment pockets.
  
• A comprehensive analysis of the factors that drive and restrict market growth is provided in the report.
  
• Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  
• Extensive analysis of the key segments of the industry helps to understand the application and products of protein chips used across the globe.
  
• Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
  

KEY MARKET SEGMENTS

By Type

• Lung Tumor-on-a-chip
  
• Bone Marrow Tumor-on-a-chip
  
• Brain Tumor-on-a-chip
  
• Breast Tumor-on-a-chip
  
• Urinary System Tumor-on-a-chip
  
• Intestine Tumor-on-a-chip
  
• Liver Tumor-on-a-chip
  

By Region

• North America
  
• U.S.
  
• Canada
  
• Mexico
  
• Europe
  
• Germany
  
• France
  
• UK
  
• Italy
  
• Spain
  
• Rest of Europe
  
• Asia-Pacific
  
• Japan
  
• China
  
• Australia
  
• India
  
• South Korea
  
• Rest of Asia-Pacific
  
• LAMEA
  
• Brazil
  
• Saudi Arabia
  
• South Africa
  
• Rest of LAMEA
  

LIST OF KEY PLAYERS PROFILED IN THE REPORT

• Axosim Technologies LLC
  
• Beonchip S. L.
  
• BioIVT LLC
  
• Emulate Inc.
  
• InSphero AG
  
• Mimetas B.V.
  
• Nortis, Inc.
  
• Organovo Holdings, Inc.